Teikoku Chemical Industries Co., Ltd.

Nagase Chemtex Corporation

Nagasaki University

Toshiharu Yanagi

Osamu Kamoda

Hiromichi Fujiwara

Osamu Onomura

Seiji Sato

Kazuya Kodama

Masami Kuriyama

Jun-ichi Mizoguchi

Eiji Tamaki

Akihiko Kitajima

Yutaro Tsuda

Akihiro Ohsako

Provided is a process for producing an optically active compound represented by Formula (3): (wherein Ris an alkyl group, an alkynyl group, an alkenyl group, an aliphatic heterocyclic group, a cycloalkyl group, an aryl group, an aralkyl group, or an aromatic heterocyclic group, and any hydrogen atom of Rmay be replaced with a substituent; Ris a hydrogen atom or a group which is not reactive in the reaction below; and * represents a chiral center) or a salt thereof by subjecting a compound represented by Formula (1): (wherein Rand Rhave the same meanings as defined in Formula (3)) to a ring closure reaction in the presence of a chiral ligand having 1 or more coordination sites, a Lewis acid represented by Formula (2):MZ&#x2003;&#x2003;(2)(wherein M is a metal ion, Z is a counter anion of M, and m and n are integers of 1 to 4), and a sulfonyl halide having an optionally substituted alkyl or phenyl group.

Method for producing optically active compound or salt thereof

The present invention relates to an ameliorant for improving the movement of the digestive tract comprising, as an active ingredient, 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-2-hydroxymethyl-4-pyrrolidinyl]benzamide or an acid addition salt thereof which is a metabolite of 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-1-ethyl-2-hydroxymethyl-4-pyrrolidinyl]benzamide or an acid addition salt thereof, having high biding affinity for a serotonin receptor 4 (5HT) and causing no arteritis and thrombus formation; a medicinal composition for improving the movement of the digestive tract comprising the said ameliorant and a pharmaceutically acceptable carrier; and a treating method for promoting the movement of the digestive tract, which comprises using the said medicinal composition for improving the movement of the digestive tract.

Medicinal composition

The invention relates to novel and valuable intermediate compounds of the general formula (VIII) which can be used for the preparation of novel compounds comprising an antibacterial action, especially with a strong antibacterial action against, and pharmaceutically acceptable salts thereof. In the general formula (VIII) X is hydrogen or halogen, Y is hydrogen or a substituted or unsubstituted aralkyloxycarbonyl group having 8-19 carbon atoms, Z is hydrogen, a substituted aralkyloxycarbonyl group having 8-19 carbon atoms or a substituted alkoxycarbonyyl group having 2-19 carbon atoms, except that X, Y and Z are all hydrogen.

Guanidinomethyl cyclohexane carboxylic acid ester derivatives

The invention relates to novel and valuable intermediate compounds of the general formula (VIII) which can be used for the preparation of novel compounds comprising an antibacterial action, especially with a strong antibacterial action against and pharmaceutically acceptable salts thereof. In the general formula (VIII) X is hydrogen or halogen, Y is hydrogen or a substituted or unsubstituted aralkyloxycarbonyl group having 8-19 carbon atoms, Z is hydrogen, a substituted aralkyloxycarbonyl group having 8-19 carbon atoms or a substituted alkoxycarbonyyl group having 2-19 carbon atoms, except that X, Y and Z are all hydrogen.

The present invention relates to a pharmaceutical composition which is appropriate for eradication or extermination of wherein &lsqb;4-&lsqb;4-(4-methylbenzyloxycarbonyl)phenyl&lsqb;phenyl trans-4-guanidinomethylcyclohexanecarboxylate or an acid addition salt thereof are compounded and it also relates to a complex consisting them.

Cyclohexane carbocyclic ester derivative and cyclodextrin complex and composition for treatment of helicobacter pylori infections

A compound represented by general formula (I-2) or a pharmaceutically acceptable acid-addition salt thereof, useful as an anti-microbial against,and as a medicinal composition for treating,infection, wherein Ar represents phenyl, biphenyl or naphthyl each having a at least one substituent selected from the group consisting of halogen, cyano, nitro, carboxy, C,-C,alkyl, C,-C,alkoxy, C,-C,cycloalkyl, C,-C,aralkyl, C,-C,arylalkenyl, C,-C,aralkyloxy, optionally substituted phenoxy, optionally substituted C,-C,alkoxycarbonyl, and optionally substituted C,-C,aralkyloxycarbonyl, provided the case where Ar represents phenyl substituted by halogen, cyano, nitro, carboxy, C,-C,alkyl, optionally substituted C,-C,alkoxycarbonyl or C,-C,aralkyloxycarbonyl is expected.

Growing community of inventors

Itami, Japan

Toshiharu Yanagi